Genmab A (GMAB) Revenue: 2018-2024
Historic Revenue for Genmab A (GMAB) over the last 7 years, with Dec 2024 value amounting to -$1.4 billion.
- Genmab A's Revenue rose 366933436.58% to $337.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $337.9 million, marking a year-over-year increase of 206.79%. This contributed to the annual value of -$1.4 billion for FY2024, which is 616.98% down from last year.
- Latest data reveals that Genmab A reported Revenue of -$1.4 billion as of FY2024, which was down 616.98% from -$200.6 million recorded in FY2023.
- Genmab A's Revenue's 5-year high stood at $1.2 billion during FY2020, with a 5-year trough of -$1.4 billion in FY2024.
- For the 3-year period, Genmab A's Revenue averaged around -$662.0 million, with its median value being -$346.9 million (2022).
- As far as peak fluctuations go, Genmab A's Revenue skyrocketed by 110.49% in 2020, and later plummeted by 616.98% in 2024.
- Genmab A's Revenue (Yearly) stood at $1.2 billion in 2020, then crashed by 112.17% to -$143.0 million in 2021, then tumbled by 142.64% to -$346.9 million in 2022, then spiked by 42.16% to -$200.6 million in 2023, then crashed by 616.98% to -$1.4 billion in 2024.